OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 91
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 91
Showing 51-75 of 91 citing articles:
Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers
Tarık Demır, Carolyn Moloney, Devalingam Mahalingam
Critical Reviews in Oncology/Hematology (2024) Vol. 199, pp. 104388-104388
Closed Access | Times Cited: 1
Tarık Demır, Carolyn Moloney, Devalingam Mahalingam
Critical Reviews in Oncology/Hematology (2024) Vol. 199, pp. 104388-104388
Closed Access | Times Cited: 1
Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies
Mar Ros-Buxó, Ezequiel Mauro, Tamara Saurí, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3615-3629
Open Access | Times Cited: 1
Mar Ros-Buxó, Ezequiel Mauro, Tamara Saurí, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3615-3629
Open Access | Times Cited: 1
CREB1 promotes cholangiocarcinoma metastasis through transcriptional regulation of the LAYN-mediated TLN1/β1 integrin axis
Shuai Liang, Shuhua Zhou, Yangshuo Tang, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e36595-e36595
Open Access | Times Cited: 1
Shuai Liang, Shuhua Zhou, Yangshuo Tang, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e36595-e36595
Open Access | Times Cited: 1
Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1/ARID1A mutations: a case report with an unexpected response
Clémentine Daugan, Romain Boidot, François Ghiringhelli, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Clémentine Daugan, Romain Boidot, François Ghiringhelli, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Hepatic Nuclear Receptors in Cholestasis-to-Cholangiocarcinoma Pathology
Inyoung Cheon, Minwook Kim, Kang Ho Kim, et al.
American Journal Of Pathology (2024)
Open Access | Times Cited: 1
Inyoung Cheon, Minwook Kim, Kang Ho Kim, et al.
American Journal Of Pathology (2024)
Open Access | Times Cited: 1
Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
ESMO Open (2024) Vol. 9, Iss. 10, pp. 103936-103936
Open Access | Times Cited: 1
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
ESMO Open (2024) Vol. 9, Iss. 10, pp. 103936-103936
Open Access | Times Cited: 1
Precision models in hepatocellular carcinoma
Marina Bárcena‐Varela, Satdarshan P. Monga, Amaia Lujambio
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 22, Iss. 3, pp. 191-205
Closed Access | Times Cited: 1
Marina Bárcena‐Varela, Satdarshan P. Monga, Amaia Lujambio
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 22, Iss. 3, pp. 191-205
Closed Access | Times Cited: 1
The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis
Zhicong Wang, Yihua Shi, Ganwei Xiong, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Zhicong Wang, Yihua Shi, Ganwei Xiong, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Molecular Analysis of Biliary Tract Cancers with the Custom 3′ RACE-Based NGS Panel
Natalia V. Mitiushkina, Vladislav I. Tiurin, Aleksandra A. Anuskina, et al.
Diagnostics (2023) Vol. 13, Iss. 20, pp. 3168-3168
Open Access | Times Cited: 3
Natalia V. Mitiushkina, Vladislav I. Tiurin, Aleksandra A. Anuskina, et al.
Diagnostics (2023) Vol. 13, Iss. 20, pp. 3168-3168
Open Access | Times Cited: 3
Evaluation of the serotonin pathway as a biomarker in cholangiocarcinoma
Christos Fountzilas, S. Velasco, Wiam Bshara, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 05, pp. 2192-2201
Open Access | Times Cited: 2
Christos Fountzilas, S. Velasco, Wiam Bshara, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 05, pp. 2192-2201
Open Access | Times Cited: 2
Immunogenomics of cholangiocarcinoma
Virag Gehl, Colm J. O’Rourke, Jesper B. Andersen
Hepatology (2023)
Closed Access | Times Cited: 2
Virag Gehl, Colm J. O’Rourke, Jesper B. Andersen
Hepatology (2023)
Closed Access | Times Cited: 2
Assessment of HER2 status of carcinomas of various localizations
С. В. Вторушин, N. V. Krakhmal, Л Э Завалишина, et al.
Russian Journal of Archive of Pathology (2023) Vol. 85, Iss. 6, pp. 31-31
Closed Access | Times Cited: 2
С. В. Вторушин, N. V. Krakhmal, Л Э Завалишина, et al.
Russian Journal of Archive of Pathology (2023) Vol. 85, Iss. 6, pp. 31-31
Closed Access | Times Cited: 2
Trailblazing TRAIL Therapy: Illuminating Pathways for Cholangiocarcinoma Treatment
Sungjin Ko
Cellular and Molecular Gastroenterology and Hepatology (2024) Vol. 17, Iss. 5, pp. 885-886
Open Access
Sungjin Ko
Cellular and Molecular Gastroenterology and Hepatology (2024) Vol. 17, Iss. 5, pp. 885-886
Open Access
Hepatic arterial infusion chemotherapy combined with bevacizumab plus a PD-1 inhibitor for gallbladder cancer with hepatic oligometastasis: a real-world study
Wenchao Zhao, Zhiyuan Yao, Jingbo Li, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 1, pp. 330-345
Open Access
Wenchao Zhao, Zhiyuan Yao, Jingbo Li, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 1, pp. 330-345
Open Access
Bile liquid biopsy is a useful modality for molecular diagnosis of cancerous tumors in pancreatic head lesions
Mika Ando, Shin Ito, Shuichi Aoki, et al.
Research Square (Research Square) (2024)
Open Access
Mika Ando, Shin Ito, Shuichi Aoki, et al.
Research Square (Research Square) (2024)
Open Access
Integrating Multi-Omics Reveals the Invasive Mechanisms and Treatment Strategies of CA19-9 Positive Intrahepatic Cholangiocarcinoma
Delin Ma, Pengcheng Wei, Hengkang Liu, et al.
(2024)
Closed Access
Delin Ma, Pengcheng Wei, Hengkang Liu, et al.
(2024)
Closed Access
Characterization of a Syngeneic Orthotopic Model of Cholangiocarcinoma by [18F]FDG-PET/MRI
Lena Zachhuber, Thomas Filip, Behrang Mozayani, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2591-2591
Open Access
Lena Zachhuber, Thomas Filip, Behrang Mozayani, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2591-2591
Open Access
Selinexor targeting XPO1 promotes PEG3 nuclear accumulation and suppresses cholangiocarcinoma progression
Deng Xiang, Min Wang, Hua‐Jun Wu, et al.
Cancer Chemotherapy and Pharmacology (2024) Vol. 94, Iss. 5, pp. 669-683
Closed Access
Deng Xiang, Min Wang, Hua‐Jun Wu, et al.
Cancer Chemotherapy and Pharmacology (2024) Vol. 94, Iss. 5, pp. 669-683
Closed Access
NSDHL promotes the degradation of sting in cholangiocarcinoma
Weihua Yu, Jionghuang Chen, Yifan Tong, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e37592-e37592
Open Access
Weihua Yu, Jionghuang Chen, Yifan Tong, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e37592-e37592
Open Access
Advances in radiomics applications for intrahepatic cholangiocarcinoma: a comprehensive review and future directions
Jiawei Xu, Binghua Li, Decai Yu
Hepatoma Research (2024)
Open Access
Jiawei Xu, Binghua Li, Decai Yu
Hepatoma Research (2024)
Open Access
Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma
Kangshuai Li, Yi Liu, Tingguo Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Kangshuai Li, Yi Liu, Tingguo Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
ASAP1 promotes extrahepatic cholangiocarcinoma progression by regulating the Wnt/β-catenin pathway in vitro and in vivo
Jiaqi He, Han Liu, Jianhua Cai, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 11, pp. 5178-5192
Closed Access
Jiaqi He, Han Liu, Jianhua Cai, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 11, pp. 5178-5192
Closed Access
Baseline and early dynamic changes in inflammatory and nutritional status can predict survival in patients with advanced biliary tract carcinoma receiving immunotherapy: A retrospective cohort study
Haoyang Shen, Xiaodong Fang, Jiaguang Zhang, et al.
journal of nutritional oncology (2024) Vol. 9, Iss. 3, pp. 81-89
Closed Access
Haoyang Shen, Xiaodong Fang, Jiaguang Zhang, et al.
journal of nutritional oncology (2024) Vol. 9, Iss. 3, pp. 81-89
Closed Access
New Relevant Evidence in Cholangiocarcinoma Biology and Characterization
N. M. Porro, Elena Spínola-Lasso, Mirella Pastore, et al.
Cancers (2024) Vol. 16, Iss. 24, pp. 4239-4239
Open Access
N. M. Porro, Elena Spínola-Lasso, Mirella Pastore, et al.
Cancers (2024) Vol. 16, Iss. 24, pp. 4239-4239
Open Access
ACSL3 is an unfavorable prognostic marker in cholangiocarcinoma patients and confers ferroptosis resistance in cholangiocarcinoma cells
Apiwit Sae-Fung, Nawaporn Vinayavekhin, Bengt Fadeel, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
Apiwit Sae-Fung, Nawaporn Vinayavekhin, Bengt Fadeel, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
